Antigen-specific T Cells Against Lung Cancer
ConditionLung Cancer
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-80
SponsorShenzhen Geno-Immune Medical Institute
About this trial
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of cancer antigen-specific T cells targeting lung cancer. The cancer targeting antigens are identified through immunostaining of patient's cancer specimens. Another goal of the study is to learn more about the persistence and function of the ex vivo manipulated antigen-specific T cells in the body.
Eligibility criteria
Qualifiers
Patients with stage III, IV or relapsed lung cancer confirmed by histology and biopsy.
Age: ≥ 18 years and ≤ 80 years.
4 weeks at least since last chemotherapy or radiotherapy and 2 weeks at least since last systemic steroid hormone and other immunosuppressive therapy.
Side Effects of Chemotherapy have subsided.
Disqualifiers
Airway obstruction caused by tumor.
History of epilepsy or other central nervous system diseases.
Patients who require systemic corticosteroid or other immunosuppressive therapy.
History of prolonged or serious heart disease during QT.
Trial design
Treatments tested in this trial
- Lung cancer-specific T cells
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov